PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cellsReportar como inadecuado

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 9:411

First Online: 25 November 2009Received: 31 December 2008Accepted: 25 November 2009DOI: 10.1186-1471-2407-9-411

Cite this article as: Crosswell, H.E., Dasgupta, A., Alvarado, C.S. et al. BMC Cancer 2009 9: 411. doi:10.1186-1471-2407-9-411


Backgroundc-Met is a tyrosine kinase receptor for hepatocyte growth factor-scatter factor HGF-SF, and both c-Met and its ligand are expressed in a variety of tissues. C-Met-HGF-SF signaling is essential for normal embryogenesis, organogenesis, and tissue regeneration. Abnormal c-Met-HGF-SF signaling has been demonstrated in different tumors and linked to aggressive and metastatic tumor phenotypes. In vitro and in vivo studies have demonstrated inhibition of c-Met-HGF-SF signaling by the small-molecule inhibitor PHA665752. This study investigated c-Met and HGF expression in two neuroblastoma NBL cell lines and tumor tissue from patients with NBL, as well as the effects of PHA665752 on growth and motility of NBL cell lines. The effect of the tumor suppressor protein PTEN on migration and proliferation of tumor cells treated with PHA665752 was also evaluated.

MethodsExpression of c-Met and HGF in NBL cell lines SH-EP and SH-SY5Y and primary tumor tissue was assessed by immunohistochemistry and quantitative RT-PCR. The effect of PHA665752 on c-Met-HGF signaling involved in NBL cell proliferation and migration was evaluated in c-Met-positive cells and c-Met-transfected cells. The transwell chemotaxis assay and the MTT assay were used to measure migration and proliferation-cell-survival of tumor cells, respectively. The PPAR-γ agonist rosiglitazone was used to assess the effect of PTEN on PHA665752-induced inhibition of NBL cell proliferation-cell-survival and migration

ResultsHigh c-Met expression was detected in SH-EP cells and primary tumors from patients with advanced-stage disease. C-Met-HGF signaling induced both migration and proliferation of SH-EP cells. Migration and proliferation-cell-survival were inhibited by PHA665752 in a dose-dependent manner. We also found that induced overexpression of PTEN following treatment with rosiglitazone significantly enhanced the inhibitory effect of PHA665752 on NBL-cell migration and proliferation.

Conclusionc-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL. Furthermore, using the NBL cell line SH-EP as a model, PHA665752 was shown to inhibit cMet-HGF-SF signaling in vitro, suggesting c-Met inhibitors may have efficacy for blocking local progression and-or metastatic spread of c-Met-positive NBL in vivo. These are novel findings for this disease and suggest that further studies of agents targeting the c-Met-HGF axis in NBL are warranted

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-9-411 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Hal E Crosswell - Anindya Dasgupta - Carlos S Alvarado - Tanya Watt - James G Christensen - Pradip De - Donald L Durden


Documentos relacionados